See more : M&F Bancorp, Inc. (MFBP) Income Statement Analysis – Financial Results
Complete financial analysis of Chinook Therapeutics, Inc. (KDNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chinook Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Grand Baoxin Auto Group Limited (1293.HK) Income Statement Analysis – Financial Results
- Nel ASA (NLLSF) Income Statement Analysis – Financial Results
- Lumentum Holdings Inc. (LU2.DE) Income Statement Analysis – Financial Results
- Sterling Infrastructure, Inc. (STRL) Income Statement Analysis – Financial Results
- 17 Education & Technology Group Inc. (YQ) Income Statement Analysis – Financial Results
Chinook Therapeutics, Inc. (KDNY)
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.13M | 51.63M | 827.00K | 17.26M | 15.09M | 17.24M | 50.68M | 72.98M |
| Cost of Revenue | 1.72M | 1.69M | 422.00K | 554.00K | 584.00K | 559.00K | 549.00K | 89.00K |
| Gross Profit | 4.41M | 49.94M | 405.00K | 16.70M | 14.50M | 16.68M | 50.13M | 72.89M |
| Gross Profit Ratio | 71.90% | 96.73% | 48.97% | 96.79% | 96.13% | 96.76% | 98.92% | 99.88% |
| Research & Development | 141.21M | 96.99M | 36.05M | 17.01M | 75.84M | 89.38M | 87.72M | 58.65M |
| General & Administrative | 36.29M | 31.90M | 19.07M | 2.96M | 36.04M | 33.75M | 34.28M | 27.81M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.29M | 31.90M | 19.07M | 2.96M | 36.04M | 33.75M | 34.28M | 27.81M |
| Other Expenses | 1.72M | 1.69M | 422.00K | 299.00K | 3.99M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 179.22M | 130.57M | 55.54M | 19.97M | 115.86M | 123.13M | 122.00M | 86.45M |
| Cost & Expenses | 179.22M | 130.57M | 55.54M | 19.97M | 116.45M | 123.69M | 122.54M | 86.54M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.18M | 0.00 | 15.00K | 33.00K | 0.00 | 0.00 | 2.22M | 494.00K |
| Depreciation & Amortization | 20.89M | 41.87M | 2.25M | 520.00K | 4.95M | 3.99M | 2.55M | 0.00 |
| EBITDA | -164.20M | -57.17M | -53.98M | -19.45M | -101.36M | -106.45M | -71.86M | -13.56M |
| EBITDA Ratio | -2,679.44% | -110.74% | -6,527.45% | -112.68% | -671.84% | -617.51% | -141.79% | -18.59% |
| Operating Income | -185.08M | -99.04M | -56.23M | -19.97M | -101.36M | -106.45M | -71.86M | -13.56M |
| Operating Income Ratio | -3,020.28% | -191.84% | -6,798.91% | -115.69% | -671.84% | -617.51% | -141.79% | -18.59% |
| Total Other Income/Expenses | 4.81M | -170.00K | -27.40M | -64.82M | 5.22M | 3.23M | 2.18M | -25.74M |
| Income Before Tax | -180.27M | -99.21M | -83.63M | -46.52M | -96.14M | -103.23M | -69.68M | -39.31M |
| Income Before Tax Ratio | -2,941.81% | -192.17% | -10,111.85% | -269.55% | -637.24% | -598.80% | -137.50% | -53.86% |
| Income Tax Expense | 4.34M | 2.09M | -2.00M | 332.00K | 783.00K | 11.36M | -21.46M | -99.00K |
| Net Income | -184.62M | -101.30M | -81.62M | -46.85M | -95.36M | -91.86M | -91.15M | -39.21M |
| Net Income Ratio | -3,012.65% | -196.22% | -9,869.65% | -271.47% | -632.05% | -532.88% | -179.85% | -53.73% |
| EPS | -2.87 | -2.22 | -6.20 | -1.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.87 | -2.22 | -6.20 | -1.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 64.37M | 45.61M | 13.17M | 42.16M | 78.81B | 72.90B | 65.20B | 44.71B |
| Weighted Avg Shares Out (Dil) | 64.37M | 45.61M | 13.17M | 42.16M | 78.81B | 72.90B | 65.20B | 44.71B |
Shareholder Alert: Ademi LLP investigates whether Chinook Therapeutics, Inc. has obtained a Fair Price in its transaction with Novartis
MILWAUKEE , June 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Chinook (Nasdaq: KDNY) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to learn how to join the action https://www.ademilaw.com/case/chinook-therapeutics-inc or call...
Novartis makes Chinook Therapeutics $3.2B offer
Chinook Therapeutics, Inc stock surged by more than half in early trade after the company said it agreed to a $40 per share buyout offer by Novartis AG (ADR) (NYSE:NVS). The $3.2 billion offer represents a 67% premium to Chinook's closing...
Why Is Chinook Therapeutics (KDNY) Stock Up 58% Today?
Chinook Therapeutics (NASDAQ: KDNY ) stock is rocketing higher on Monday after the company announced it's being acquired by Novartis AG (NYSE: NVS ). Novartis AG is acquiring Chinook Therapeutics in a $3.2 billion deal.
KDNY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chinook Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chinook Therapeutics, Inc. (NASDAQ: KDNY) to Novartis AG for $40.00 per share in cash is fair to Chinook shareholders. Additionally, Chinook shareholders will receive...
Chinook Therapeutics Stock Surges After Novartis Agrees $3.5 Billion Deal
Chinook said it has entered an agreement to be acquired by Novartis for $40 per share in cash, with additional cash contingent on regulatory progress with astrasentan, its kidney disease drug candidate.
Chinook Therapeutics stock surges on deal to be bought for up to $3.5 billion by Novartis
Shares of Chinook Therapeutics KDNY, +0.17% rose 67% to $40.02 after it agreed to be bought by Novartis NVS, +0.28% for up to $3.5 billion. Holders of Chinook will receive $3.2 billion, or $40 per share, in cash upon closing,...
Novartis agrees to buy Chinook Therapeutics for up to $3.5 billion
Novartis agreed to acquire clinical-stage biopharmaceutical company Chinook Therapeutics for up to $3.5 billion, in a deal that will expand its portfolio of kidney disease treatments.
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that it has entered into an agreement and plan of...
CHINOOK SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options
NEW YORK , June 10, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). If you suffered losses exceeding $50,000 investing in...
CHINOOK INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options
NEW YORK , June 3, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). If you suffered losses exceeding $50,000 investing in...
Source: https://incomestatements.info
Category: Stock Reports